Baseline characteristics and treatment and imaging between the discordant and concordant disease progression subgroups were well balanced (table 1 and online supplemental table 3); key laboratory values and biomarkers (serum levels of albumin, C-reactive protein, lymphocytes, neutrophils, platelets, and leukocytes; neutrophil/lymphocyte ratio; Fc-gamma receptor single-nucleotide polymorphisms; major histocompatibility complex class I and II genes; killer cell immunoglobulin-like receptor genes; and tumor mutational burden) were also balanced across subgroups (data not shown). The gene discussed is KIR3DL2; the disease is neoplasm.